Zurzuvae PPD denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Zurzuvae for PPD

Aetna's pharmacy benefit imposes quantity limits on Zurzuvae (zuranolone) that are designed to align with the FDA-approved treatment course for postpartum depression. A quantity-limit denial typically occurs when a prescription is written for a supply that exceeds the plan's approved quantity, the fill is being requested sooner than the plan's refill window permits, or the patient has already received the quantity Aetna considers consistent with a single treatment course and requires additional supply.

## Why This Denial Is Appealable

Quantity limits are a form of benefit limitation subject to appeal as an adverse benefit determination under ACA §2719 and ERISA §503. If the treating clinician documents a clinical reason that the standard quantity limit does not meet this patient's needs — for example, a need for retreatment supported by medical documentation — you have the right to an exception and to internal and external review of any denial.

## Federal Appeal Framework

• Quantity-limit exception request: File with Aetna's pharmacy benefit department with a supporting prescriber letter before or alongside a formal internal appeal.
• Internal appeal: If the exception is denied, submit a formal internal appeal within the timeframe in the denial notice. The plan must respond within 60 days for standard post-service appeals.
• External review (ACA §2719): After final internal denial, you have approximately 4 months to request independent external review.
• Expedited review: Available where delay poses a serious health risk; required turnaround is 72 hours.

## Documentation to Gather

1. Prescriber's clinical justification: A letter from the treating clinician or psychiatrist explaining the clinical basis for the prescribed quantity, referencing the FDA-approved prescribing label and stating whether this represents an initial course or a subsequent course of treatment. 2. Diagnosis and treatment timeline: Chart documentation confirming the PPD diagnosis, treatment start date, and the clinical rationale for the current prescription. 3. FDA label reference: The prescribing label's guidance on treatment duration and retreatment, as interpreted by the treating clinician for this patient's specific clinical situation. Do not quote numbers — direct the reviewer to the label itself. 4. Aetna quantity-limit criteria: Obtain Aetna's stated quantity limit for Zurzuvae in writing. Confirm whether the prescribed quantity falls outside it and why the prescriber believes the limit does not serve this patient's clinical needs. 5. Prior fill history: Pharmacy records documenting any prior fills, the dates, and the clinical outcomes noted in the chart.

## Criteria-Mapping Structure

In your appeal letter:

• Aetna's quantity limit (verbatim from policy or denial letter): [paste exact language]
• Prescribed quantity and clinical rationale: [from prescriber letter and chart notes]
• FDA label support: [reference the label without quoting specific quantities — direct the reviewer to the source]

Attach the prescriber letter, pharmacy fill history, and relevant chart notes as labeled exhibits. Quantity-limit exceptions supported by a clear clinical rationale and FDA label alignment have a strong basis for reversal at the internal appeal level.